Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $60.42, but opened at $57.00. Zealand Pharma A/S shares last traded at $57.00, with a volume of 442 shares trading hands.

Analysts Set New Price Targets

Several brokerages have issued reports on ZLDPF. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Five investment analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy”.

Zealand Pharma A/S Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10. The business has a 50 day simple moving average of $67.19 and a 200-day simple moving average of $70.75. The firm has a market cap of $4.05 billion, a price-to-earnings ratio of 4.17 and a beta of 0.72.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.34) by $0.53. The firm had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. Zealand Pharma A/S had a return on equity of 49.76% and a net margin of 70.06%. Equities research analysts expect that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.